Extended Data Table 1.
Neutralization, V gene usage and other properties of tested mAbs.
| mAb | Domain (site) | VH usage (% id.) | Source (DSO) | IC50 WT (ng/ml) | IC50 B.1.1.7 (ng/ml) | ACE2 blocking | SARS-CoV | Escape residues | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| 4A8 | NTD (i) | 1–24 | N/A | 38 | Neg. | S12P; C136Y; Y144del; H146Y; K147T; R246A | 60 | ||
| S2L26 | NTD (i) | 1–24 (97.2) | Hosp. (52) | 70 | - | Neg. | N/A | 24 | |
| S2L50 | NTD (i) | 4–59 (95.4) | Hosp. (52) | 264 | 50 | Neg. | N/A | 24 | |
| S2M28 | NTD (i) | 3–33 (97.6) | Hosp. (46) | 295 | 12′207 | Neg. | P9S/Q;S12P; C15F/R; L18P; Y28C; A123T; C136Y; G142D; Y144del; K147Q/T; R246G;P251L; G252C | 24 | |
| S2X107 | NTD (i) | 4-38-2 (97) | Sympt. (75) | 388 | Neg. | N/A | 24 | ||
| S2X124 | NTD (i) | 3–30 (99) | Sympt. (75) | 221 | - | Neg. | - | N/A | 24 |
| S2X158 | NTD (i) | 1–24 (96.3) | Sympt. (75) | 56 | - | Neg. | - | N/A | 24 |
| S2X28 | NTD (i) | 3–30 (97.9) | Sympt. (48) | 1’399 | Neg. | P9S; S12P; C15W; L18P; C136G/Y; F140S; L141S; G142C/D; Y144C/N; K147T/Q/E; R158G; L244S; R246G | 24 | ||
| S2X303 | NTD (i) | 2–5 (95.9) | Sympt. (125) | 69 | - | Neg. | - | N/A | 24 |
| S2X333 | NTD (i) | 3–33 (96.5) | Sympt. (125) | 66 | Neg. | P9L; S12P; C15S/Y; L18P; C136G/Y; F140C; G142D; K147T | 24 | ||
| S2D106 | RBD (I/RBM) | 1–69 (97.2) | Hosp. (98) | 27 | 20 | Strong | - | N/A | 8 |
| S2D19 | RBD (I/RBM) | 4–31 (99.7) | Hosp. (49) | 128 | 75’200 | Moderate | - | N/A | 8 |
| S2D32 | RBD (I/RBM) | 3–49 (98.3) | Hosp. (49) | 26 | 11 | Strong | - | N/A | 8 |
| S2D65 | RBD (I/RBM) | 3–9 (96.9) | Hosp. (49) | 24 | 12 | Weak | N/A | 8 | |
| S2D8 | RBD (I/RBM) | 3–23 (96.5) | Hosp. (49) | 27 | 58′644 | Strong | - | N/A | 8 |
| S2D97 | RBD (I/RBM) | 2–5 (96.9) | Hosp. (98) | 20 | 17 | Weak | N/A | 8 | |
| S2E11 | RBD (I/RBM) | 4–61 (98.3) | Hosp. (51) | 27 | 16 | Weak | - | N/A | 8 |
| S2E12 | RBD (I/RBM) | 1–58 (97.6) | Hosp. (51) | 27 | 31 | Strong | - | G476S (3x) | 8,61 |
| S2E13 | RBD (I/RBM) | 1–18(96.2) | Hosp. (51) | 34 | 77 | Strong | - | N/A | 8 |
| S2E16 | RBD (I/RBM) | 3–30 (98.3) | Hosp. (51) | 36 | 38 | Strong | - | N/A | 8 |
| S2E23 | RBD (I/RBM) | 3–64 (96.9) | Hosp. (51) | 139 | 180 | Strong | - | N/A | 8 |
| S2H14 | RBD (I/RBM) | 3–15(100) | Sympt. (17) | 460 | 64′463 | Weak | - | N/A | 8,62 |
| S2H19 | RBD (I/RBM) | 3–15(98.6) | Sympt. (45) | 239 | - | Weak | - | N/A | 8 |
| S2H58 | RBD (I/RBM) | 1–2(97.9) | Sympt. (45) | 27 | 14 | Strong | - | N/A | 8 |
| S2H7 | RBD (I/RBM) | 3–66 (98.3) | Sympt. (17) | 492 | 573 | Weak | N/A | 8 | |
| S2H70 | RBD (I/RBM) | 1–2 (99) | Sympt. (45) | 147 | 65 | Weak | - | N/A | 8 |
| S2H71 | RBD (I/RBM) | 2–5 (99) | Sympt. (45) | 36 | 9 | Moderate | - | N/A | 8 |
| S2M11 | RBD (I/RBM) | 1–2 (96.5) | Hosp. (46) | 11 | 4 | Weak | Y449N; L455F; E484K; E484Q; F490L; F490S; S494P | 8,61 | |
| S2N12 | RBD (I/RBM) | 4–39 (97.6) | Hosp. (51) | 76 | 40 | Strong | - | N/A | 8 |
| S2N22 | RBD (I/RBM) | 3–23 (96.5) | Hosp. (51) | 32 | 21 | Strong | N/A | 8 | |
| S2N28 | RBD (I/RBM) | 3–30 (97.2) | Hosp. (51) | 72 | 21 | Strong | - | N/A | 8 |
| S2X128 | RBD (I/RBM) | 1-69-2 (97.6) | Sympt. (75) | 50 | 112 | Strong | N/A | 8 | |
| S2X16 | RBD (I/RBM) | 1–69 (97.6) | Sympt. (48) | 45 | 103 | Strong | N/A | 8 | |
| S2X192 | RBD (I/RBM) | 1–69 (96.9) | Sympt. (75) | 326 | - | Weak | - | N/A | 8 |
| S2X227 | RBD (I/RBM) | 1–46 (97.9) | Sympt. (75) | 26 | 14 | Strong | N/A | ||
| S2X246 | RBD (I/RBM) | 3–48 (96.2) | Sympt. (75) | 35 | 30 | Strong | N/A | ||
| S2X30 | RBD (I/RBM) | 1–69 (97.9) | Sympt. (48) | 32 | 53 | Strong | - | N/A | 8 |
| S2X324 | RBD (I/RBM) | 2–5 (97.3) | Sympt. (125) | 8 | 23 | Strong | - | N/A | |
| S2X58 | RBD (I/RBM) | 1–46 (99) | Sympt. (48) | 32 | 47 | Strong | N/A | 8 | |
| S2H90 | RBD (II) | 4–61 (96.6) | Sympt. (81) | 77 | 32 | Strong | + | N/A | 8 |
| S2H94 | RBD (II) | 3–23 (93.4) | Sympt. (81) | 123 | 144 | Strong | + | N/A | 8 |
| S2H97 | RBD (V) | 5–51 (98.3) | Sympt. (81) | 513 | 248 | Weak | + | N/A | |
| S2K15 | RBD (II) | 2–26 (99.3) | Sympt. (87) | 361 | 235 | 0 | + | N/A | |
| S2K21 | RBD (II) | 3–33 (96.2) | Sympt. (118) | 201 | 189 | 0 | + | N/A | |
| S2K30 | RBD (II) | 1–2(97.2) | Sympt. (87) | 185 | 134 | 0 | + | N/A | |
| S2K63v2 | RBD (II) | 3-30-3 (95.6) | Sympt. (118) | 144 | 215 | 0 | + | N/A | |
| S2L17 | RBD (?) | 5-10-1(98.3) | Hosp. (51) | 313 | 127 | Moderate | + | N/A | 8 |
| S2L49 | RBD (?) | 3–30 (97.9) | Hosp. (51) | 24 | 32 | Neg. | + | N/A | 8 |
| S2X259 | RBD (IIa) | 1–69 (94.1) | Sympt. (75) | 145 | 91 | Moderate | + | N/A | |
| S2X305 | RBD (?) | 1–2(95.1) | Sympt. (125) | 34 | 21 | Strong | N/A | ||
| S2X35 | RBD (IIa) | 1–18(98.6) | Sympt. (48) | 140 | 143 | Strong | + | N/A | |
| S2X450 | RBD (?) | 2–26 (96.9) | Sympt. (271) | 368 | 198 | Strong | + | N/A | |
| S2X475 | RBD (?) | 3–21 (93.8) | Sympt. (271) | 1′431 | 851 | Strong | + | N/A | |
| S2X607 | RBD (?) | 3–66 (95.4) | Sympt. (271) | 41 | 23 | Strong | N/A | ||
| S2X608 | RBD (?) | 1–33 (93.2) | Sympt. (271) | 21 | 35 | Strong | - | N/A | |
| S2X609 | RBD (?) | 1–69 (93.8) | Sympt. (271) | 47 | 35 | Strong | - | N/A | |
| S2X613 | RBD (I) | 1–2(91.7) | Sympt. (271) | 28 | 19 | Strong | N/A | ||
| S2X615 | RBD (I) | 3–11 (94.8) | Sympt. (271) | 23 | 17 | Strong | - | N/A | |
| S2X619 | RBD (?) | 1–69 (92.7) | Sympt. (271) | 36 | 60 | Strong | - | N/A | |
| S2X620 | RBD (?) | 3–53 (95.1) | Sympt. (271) | 34 | 45 | Strong | N/A |
id., identity. DSO, days after symptom onset. * as described in Piccoli et al and McCallum et al. N/A, not available; -, not neutralising